- Report
- April 2024
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- March 2024
- 1200 Pages
Global
From €4054EUR$4,200USD£3,477GBP
- Report
- March 2024
- 188 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- March 2024
- 188 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- March 2024
- 186 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- November 2023
- 190 Pages
Global
From €1921EUR$1,990USD£1,648GBP
- Report
- January 2024
- 182 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 180 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- October 2023
- 190 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- August 2023
- 168 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Drug Pipelines
- August 2023
- 580 Pages
United States
From €4054EUR$4,200USD£3,477GBP
- Report
- January 2023
- 441 Pages
Global
From €6752EUR$6,995USD£5,791GBP
- Report
- November 2020
- 450 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- August 2019
- 580 Pages
Global
From €3860EUR$3,999USD£3,311GBP
- Report
- January 2023
- 315 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- December 2022
- 363 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- October 2022
- 640 Pages
Global
From €4632EUR$4,799USD£3,973GBP
- Report
- July 2019
- 800 Pages
Global
From €4342EUR$4,499USD£3,725GBP
- Report
- August 2022
- 1180 Pages
Global
From €5694EUR$5,899USD£4,884GBP
Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers.
Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more